C-reactive protein, or CRP, is a blood marker of inflammation. Research on GLP-1 drugs and inflammation uses markers like CRP to track changes during treatment. The same percentage change in body weight and CRP would describe different outcomes.
What the review found
The review included nine trials with 6,239 adults who had overweight or obesity without diabetes [1]. Compared with placebo, semaglutide lowered body weight by 12.04 percentage points more from baseline. The 95% confidence interval for that reduction was 11.00 to 13.08 points. Waist circumference fell 9.36 cm more than with placebo.
The pooled difference in CRP change was 40.90 percentage points in favor of semaglutide [1]. The 95% confidence interval was 35.42 to 46.37 points. The studies used different doses and follow-up periods. The review could not separate the effects of weight loss from other possible causes of the CRP changes.
What it found about serious adverse events
The pooled risk ratio for serious adverse events was 1.12, with a 95% confidence interval of 0.76 to 1.65 [1]. Studies of specific digestive side effects address a different question from counting all serious events. The interval leaves room for a lower or higher rate with semaglutide.